How many days does avatrombopag (Su Kexin) start to take effect in treating platelets?

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), mainly used to treat patients with chronic liver disease-related thrombocytopenia and immune thrombocytopenia (ITP). It simulates the effect of thrombopoietin (TPO), stimulating the differentiation and proliferation of bone marrow megakaryocytes, thereby increasing platelet production and providing patients with a treatment method to quickly increase platelet count.

Clinical studies have shown that signs of platelet elevation usually begin 3–5 days after use of avatrombopag. For patients with chronic liver disease-related thrombocytopenia, some studies have shown that platelet counts can reach levels that allow for safe surgery or invasive procedures around day 5 of dosing. For patients with immune thrombocytopenia, the onset of effect may be slightly delayed, but most patients can observe a significant increase in platelets within 1 of continuous medication.

The difference in onset of effect is mainly related to the patient's basal platelet level, bone marrow hematopoietic function, comorbid diseases, and drug dosage. Patients with extremely low basal platelets or severe myelosuppression may have slower platelet elevations; at the same time, abnormal liver function may also affect drug metabolism and bioavailability, thereby prolonging the onset of action. Therefore, in clinical use, it is necessary to rationally adjust the dose and evaluate the efficacy based on the specific conditions of the patient.

Overall, avatrombopag has a faster onset of action and is an effective choice for clinical treatment of elevated platelets. To ensure the safety and efficacy of treatment, patients should regularly monitor their platelet count during medication and adjust the dose in a timely manner based on changes in platelets. Doctors usually continue to maintain or gradually discontinue the drug according to the treatment goals after the patient's platelets reach the target level to avoid the risk of blood clots caused by excessive platelets.

Reference materials:https://www.drugs.com/